Full-year outlook raised, new Group management team appointed
. Group sales up 3.1 billion to 36.4 billion Swiss francs in first nine months, an increase of 11% in local currencies (9% in Swiss francs); both divisions grow significantly faster than their respective markets1
. Genentech integration progressing successfully
. New Group leadership appointed
Sales in millions of CHF Nine months ended 30. Sep % change
2009 2008 In CHF In LC* In USD
Pharmaceuticals Division 29,034 26,193 11 12 6
Europe/Rest of World 14,387 13,869 4 13 -1
United States 11,157 10,090 11 6 6
Japan 3,490 2,234 56 34 49
Diagnostics Division 7,365 7,112 4 8 -1
Roche Group 36,399 33,305 9 11 4

* LC= local currencies
See appendix to this media release for details of quarterly sales growth

Full-year outlook raised
. Roche now expects at least high single-digit full-year sales growth for Pharmaceuticals Division; full-year 2009 sales in both divisions expected to grow well ahead of market
. Roche confirms target of double-digit Core EPS growth in 2009 and 2010 (at constant exchange rates)Pharmaceuticals Division sustains growth at twice the market average
. Pharma sales grow 12% (11% in Swiss francs) driven by continued strong performance of leading anticancer medicines, Lucentis, Pegasys and Mircera . Strong demand for Tamiflu continues in third quarter: full-year sales expectation raised from 2.0 to around 2.7 billion francs in 2009 and from 400 million to about 700 million francs in 2010
. MabThera receives EU approval for the treatment of relapsed or refractory chronic lymphocytic leukemia
. Avastin receives US FDA approval for kidney cancer and broader EU approval for breast cancer
. Positive market response to ongoing rollout of RoActemra in EU, market penetration of Actemra in Japan progressing wellDiagnostics Division significantly outperforms the market